Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32678716

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2020 Sep 20
First author
Saura C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2021 Jan 20;39(3):251-252. doi: 10.1200/JCO.20.02385.
    note
    Source null
    related pmid
    33332187
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2021 Jan 20;39(3):254-255. doi: 10.1200/JCO.20.02963.
    note
    Source null
    related pmid
    33332192
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2021 Jan 20;39(3):253-254. doi: 10.1200/JCO.20.02355.
    note
    Source null
    related pmid
    33332193
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2021 Jan 20;39(3):252-253. doi: 10.1200/JCO.20.02378.
    note
    Source null
    related pmid
    33332194
    relationship
    Comment in

Authors and identifiers

  1. name
    Saura C
    type
    Author
  2. name
    Oliveira M
    type
    Author
  3. name
    Feng YH
    type
    Author
  4. name
    Dai MS
    type
    Author
  5. name
    Chen SW
    type
    Author
  6. name
    Hurvitz SA
    type
    Author
  7. name
    Kim SB
    type
    Author
  8. name
    Moy B
    type
    Author
  9. name
    Delaloge S
    type
    Author
  10. name
    Gradishar W
    type
    Author
  11. name
    Masuda N
    type
    Author
  12. name
    Palacova M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Saura C
    type
    Author
  2. name
    Oliveira M
    type
    Author
  3. name
    Feng YH
    type
    Author
  4. name
    Dai MS
    type
    Author
  5. name
    Chen SW
    type
    Author
  6. name
    Hurvitz SA
    type
    Author
  7. name
    Kim SB
    type
    Author
  8. name
    Moy B
    type
    Author
  9. name
    Delaloge S
    type
    Author
  10. name
    Gradishar W
    type
    Author
  11. name
    Masuda N
    type
    Author
  12. name
    Palacova M
    type
    Author
bibliography ids
  1. nci-bib-0f5ed7f0ad472b0b44129b2d
book metadata
content sha256
54cbab54301a5d6dcf5a10e1ab5b2808c23c4cb92375cabcf623bd98f267dabd
document type
citation
dois
  1. 10.1200/JCO.20.00147
electronic publication date
display
2020 Jul 17
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32678716
immutable id
pubmed:32678716@54cbab54301a5d6dcf5a10e1ab5b2808c23c4cb92375cabcf623bd98f267dabd
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
27
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3138-3149
volume
38
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2021 Jan 20;39(3):251-252. doi: 10.1200/JCO.20.02385.
    note
    Source null
    related pmid
    33332187
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2021 Jan 20;39(3):254-255. doi: 10.1200/JCO.20.02963.
    note
    Source null
    related pmid
    33332192
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2021 Jan 20;39(3):253-254. doi: 10.1200/JCO.20.02355.
    note
    Source null
    related pmid
    33332193
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2021 Jan 20;39(3):252-253. doi: 10.1200/JCO.20.02378.
    note
    Source null
    related pmid
    33332194
    relationship
    Comment in
outcomes validated
false
pmid
32678716
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
65a8614ca38fc56b37633e748e3a5e824a648ab90a9d529621a86aea64151f30
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Sep 20
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32678716/
title
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.

Preserved source evidence · Not medical advice